Yu Jixian

Dr. Yu Jixian


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
XWXiaomin Wu
Xiaomin Wu
YWYi Wang
Yi Wang
LTLeilei Tao
Leilei Tao
YZYi Zhou
Yi Zhou
XLXiaojing Lv
Xiaojing Lv
YJYu Jixian
Yu Jixian
Hepatocellular carcinoma is the most common form of liver tumor. m6A modification and noncoding RNA show indispensable roles in HCC. We sought to establish and verify an appropriate m6A-related long noncoding RNA prognostic tool for predicting hepatocellular carcinoma progression. We extracted the RNA expression levels and the clinicopathologic data from GTEx and TCGA databases. Multivariate Cox regression analysis and receiver operating characteristic curves were performed to test the models predictive ability. We further built a nomogram for overall survival according to the risk score and clinical features. A competing endogenous RNA network and Gene Ontology assessment were implemented to identify related biological mechanisms and processes. By bioinformatics analysis, a risk model comprising GABPB1-AS1, AC025580.1, LINC01358, AC026356.1, AC009005.1, HCG15, and AC026368.1 was built to offer a prognostic prediction for hepatocellular carcinoma independently. The prognostic tool could better prognosticate hepatocellular carcinoma patients’ survival than other clinical characteristics. Then, a nomogram with risk score and clinical characteristics was created, which had strong power to calculate the survival probability in hepatocellular carcinoma. The immune-associated processes involving the differentially expressed genes between the two subgroups were displayed. Analyses of prognosis, clinicopathological characteristics, tumor mutation burden, immune checkpoint molecules, and drug response showed significant differences among the two risk subtypes, hinting that the model could appraise the efficacy of immunotherapy and chemotherapy. The tool can independently predict the prognosis in patients with hepatocellular carcinoma, which benefits drug selection in hepatocellular carcinoma patients.

14 June 2024 in Hepatology
Verified
Journal Article
Closed access
XLXin Luo
Xin Luo
YJYu Jixian
Yu Jixian
An abstract is unavailable. This article is available as a PDF only.

25 June 2024 in Hepatology
Verified
Journal Article
Closed access
XLXin Luo
Xin Luo
YJYu Jixian
Yu Jixian
An abstract is unavailable. This article is available as a PDF only.